PMDT

Programmatic Management of Drug-resistant TB (PMDT): While the causes of multi-drug resistant TB are similar in all high burden countries
(low adherence, weak DOTS, poor treatment compliance, inadequate drug supplies, direct transmission, etc.).

Community Based Care for Drug-Resistant TB: A Guide for Implementers

Many countries are in the process of establishing or scaling up treatment of drug-resistant tuberculosis (DR TB). Effectively scaling up treatment will require addressing health systems–related issues, such as task shifting to alleviate human resources shortages and greater community engagement. A principal challenge in establishing or scaling up treatment of DR TB is deciding what model of care to implement. A crucial step is bridging the gap between the hospital and the community to ensure continuity of care. For DR TB treatment to be truly patient-centered, patients must be supported in their homes and communities.

WHO Global Report: Multidrug and extensively drug-resistant TB (M/XDR-TB) - 2010 GLOBAL REPORT ON SURVEILLANCE AND RESPONSE

This report on TB drug resistance by the World Health Organization (WHO) updates “Anti-tuberculosis drug resistance in the world: Report No. 4” published by WHO in 2008. It summarizes the latest data and provides latest estimates of the global epidemic of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB). For the first time, this report includes an assessment of the progress countries are making to diagnose and treat MDR-TB cases.

Pages